000			03929nam a22003735i 4500
001			391928
003			ES-MaUEC
005			20230102122629.0
007			cr nn 008mamaa
008			111028s2011 xxu| s |||| 0|eng d
020			_a9781617793707
024	7		_a10.1007/978-1-61779-370-7 _2doi
040			_aES-MaUEC _bspa _cES-MaUEC
245	1	0	_aAdeno-Associated Virus _bMethods and Protocols _cedited by Richard O. Snyder, Philippe Moullier.
250			_a1st edition 2011
264		1	_aTotowa, NJ _bHumana Press _c2011
300			_a1 recurso en línea (XIII, 462 páginas) _b43 ilustraciones, 20 ilustraciones a color
336			_atexto _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
347			_aarchivo de texto _bPDF
490	0		_aMethods in Molecular Biology _x1940-6029 _v807
505	0		_aAdeno-Associated Virus Biology -- Design and Construction of Functional AAV Vectors -- AAV Capsid Structure and Cell Interactions -- Exploiting Natural Diversity of AAV for the Design of Vectors With Novel Properties -- Gene Therapy in Skeletal Muscle Mediated by Adeno-Associated Virus (AAV) Vectors -- AAV-Mediated Liver-Directed Gene Therapy -- Recombinant AAV Delivery to the Central Nervous System -- AAV Mediated Gene Therapy for Retinal Degenerative Diseases -- Adeno-Associated Virus Vector Delivery to the Heart -- Evaluation of the Fate of rAAV Genomes Following in vivo Administration -- Measuring Immune Responses to Recombinant AAV Gene Transfer -- Modification and Labeling of AAV Vector Particles -- AAV-mediated Gene Targeting -- Preclinical Study Design for rAAV -- Biodistribution and Shedding of AAV Vectors -- Production and Purification of Recombinant Adeno-Associated Vectors -- rAAV Vector Product Characterization and Stability Studies -- rAAV Human Trial Experience.
520			_aToday, progress in rAAV-mediated gene transfer is so robust that long-term, efficient, and regulatable transgene expression is reproducibly achieved in large animal models. The complexity of  gene transfer agents in the context of their clinical use requires investigators from a wide variety of backgrounds to have an understanding - or at least an appreciation of - the regulatory environment and constraints that affect vector design, manufacturing, pre-clinical testing, and clinical use, with an emphasis on patient protection. In Adeno-Associated Virus: Methods and Protocols, experts from the United States and Europe have contributed current knowledge of this multi-dimensional field relating to the biology of AAV, rAAV vector design, vector manufacturing and product testing, performance of rAAV vectors in major organs, rAAV-related immunological issues, design of animal and clinical studies, and clinical experience. Written in the successful Methods in Molecular Biology™ series format, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible protocols, and notes on troubleshooting and avoiding known pitfalls.   Authoritative and accessible, Adeno-Associated Virus: Methods and Protocols provides a complete and comprehensive understanding of this multi-disciplinary and rapidly progressing field.
700	1		_aSnyder, Richard O _eeditor literario _4edt _4http://id.loc.gov/vocabulary/relators/edt
700	1		_aMoullier, Philippe _eeditor literario _4edt _4http://id.loc.gov/vocabulary/relators/edt
776	0	8	_iPrinted edition: _z9781617793691
776	0	8	_iPrinted edition: _z9781617793714
776	0	8	_iPrinted edition: _z9781493961757
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-1-61779-370-7 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942			_2lcc _cLE
988			_aSpringer_Protocols_2011
999			_c391928 _d391928